drugset / Trial / NCT00003307

Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer

NCT00003307

Treatment

Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Amifostine may protect normal cells from the side effects of radiation therapy. PURPOSE: Phase II trial to study the effectiveness of radiation therapy plus amifostine in treating patients with primary prostate cancer.

Timeline

Start
1998-03
Primary completion
2001-06
Completion
2001-06

Drugs

EvaluationDrugModalityDoseRoute
Subject amifostine Unknown Intravenous